...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Epidemiology >Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study Team.
【24h】

Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study Team.

机译：3845名高脂血症患者中非依从人群的氟伐他汀治疗依从性特征。 CREOLE研究团队。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The objectives of the study were to analyze 1) compliance with an HMG-CoA reductase inhibitor, 2) the relationship between treatment compliance and sociodemographic, clinical, and psychological criteria, and 3) the effect of raising patients' awareness through distribution of an information notice. The results analyzed in this article compare the noncompliant and compliant population independently of awareness. This open-label study was conducted in two randomized parallel groups: a control group that received the information normally given by the practitioners, and an awareness group that received specific informational brochures on diet and cardiovascular risk factors and the reasons for the treatment. Male and female patients (n = 3845) aged 18 to 75 years with primary hypercholesterolemia (type IIa and IIb), not taking a cholesterol-lowering drug or for whom an ongoing treatment was poorly tolerated or ineffective, were to be included. Cholesterol levels had to be greater than 250 mg/dL (or 200 mg/dL if previous coronary history) and triglyceride levels less than 350 mg/dL. A total of 2888 subjects (75%) were defined as compliant (taking more than 90% of the prescription) and 957 (25%) noncompliant. Both populations are identical for age, sex ratio, and different risk factors, with the exception of diabetes. The adverse effects in noncompliant subjects were very clearly different, with an overrepresentation of gastrointestinal and neurologic effects and the noncompliant patients more frequently having more than one adverse effect. Noncompliant patients had an identical duration of follow-up, and the number of patients claiming to have a symptom related to hypercholesterolemia, self-evaluation of cardiovascular risk level, and source of knowledge about cholesterol and diet was similar in both groups. In contrast, in the noncompliant group, there were a larger number of symptomatic patients who thought the drug did not improve the symptoms. In practice, these results show that physicians should systematically evaluate compliance by looking for and analyzing adverse effects and by reassuring the patient when these effects are minor or probably unrelated to the treatment. Diabetics and polymedicated patients deserve special attention in this regard.
机译：该研究的目的是分析1）对HMG-CoA还原酶抑制剂的依从性，2）治疗依从性与社会人口统计学，临床和心理标准之间的关系，以及3）通过分发信息来提高患者意识的效果注意。本文分析的结果独立于意识之外，比较了不合规人群和合规人群。这项开放标签研究在两个随机平行组中进行：一个对照组，接受从业人员通常提供的信息，一个意识组，接受有关饮食和心血管危险因素以及治疗原因的特定信息手册。年龄在18至75岁之间的原发性高胆固醇血症（IIa和IIb型），未服用降胆固醇药物或正在进行的治疗耐受性差或无效的男性和女性患者（n = 3845）。胆固醇水平必须大于250 mg / dL（如果以前有冠脉病史，则必须大于200 mg / dL），甘油三酯水平必须小于350 mg / dL。共有2888名受试者（75％）被确定为合规（服用处方的90％以上）和957名（25％）不合规。除糖尿病外，两个人群的年龄，性别比和不同的危险因素均相同。非依从性受试者的不良反应非常明显，其中胃肠道和神经系统作用的代表过多，并且非依从性患者更经常产生一种以上的不良反应。非依从性患者的随访时间相同，两组中自称患有高胆固醇血症，心血管风险水平的自我评估以及胆固醇和饮食知识来源的患者数量相似。相反，在不依从组中，有大量有症状的患者认为该药物不能改善症状。在实践中，这些结果表明，医师应通过寻找和分析不良反应并在这些影响较小或可能与治疗无关的情况下向患者放心，系统地评估依从性。糖尿病和多药患者在这方面值得特别注意。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号